Form 4: Rhythm Pharmaceuticals Director Lynn A. Tetrault Reports Stock Option and Restricted Stock Unit Grants

Director Lynn A. Tetrault reports the acquisition of stock options and restricted stock units in Rhythm Pharmaceuticals.

Summary

• On June 18, 2024, Lynn A. Tetrault, a director of Rhythm Pharmaceuticals, reported the acquisition of 14,000 stock options and 4,000 restricted stock units (RSUs).
• The stock options have an exercise price of $41.39 and expire on June 17, 2034.
• Both the stock options and RSUs vest fully upon the earlier of June 18, 2025, or the date of the Issuer's annual meeting of stockholders in 2025, contingent upon continued service.
• The RSUs represent a contingent right to receive one share of Rhythm Pharmaceuticals common stock each and have no expiration date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The grant of equity can be seen as a positive sign of aligning director interests with shareholders, but it's a routine event.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company's success.

Industry Context

This filing is a routine disclosure of equity grants to a company director, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the pharmaceutical industry.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also grant stock options and RSUs to their directors as part of their compensation packages.
• The vesting schedules and terms are generally in line with industry standards, aiming to align director interests with long-term shareholder value.

Stakeholder Impact

• The grant of equity to a director can positively impact shareholders by aligning management's interests with long-term company performance.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates